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Eliminating tuberculosis by 2035: tackling the
financial barriers at all stages of the cascade of
care
We welcome the recent paper by Pedrazzoli et al.1
that discusses how to measure the economic burden
for tuberculosis (TB) patients, and outlines how this
information can inform policies for better social and
financial protection. The current methodology, how-
ever, only includes TB patients enrolled and retained
in care. While the paper mentions the need to assess
patients who are lost to follow-up between diagnosis
and treatment (pre-treatment loss to follow-up), or
during treatment, we feel that earlier aspects of the
cascade of care also need emphasis—especially if we
are to make the goal of eliminating TB by 2035 a
reality.
Two recent studies in Zimbabwe highlight the huge
pre-diagnostic losses to follow-up that can occur
between onset of symptoms, when patients are
identified as having presumptive TB, and laboratory
diagnosis.2,3 The first study found that 55% of HIV-
infected persons with presumptive TB who should
have had a diagnostic Xpertw MTB/RIF assay
(Cepheid, Sunnyvale, CA, USA) failed to have the
test done,2 and the second study conducted in Guruve
(a rural district) found that 19% of nearly 3000
persons with presumptive TB failed to be investigated
in a district laboratory.3 In Guruve, an important risk
factor was distance between the health facility that
registered the presumptive TB patients and the
laboratory tasked with analysing the specimens.
Other risk factors for pre-diagnostic loss to follow-
up include TB-related stigma, direct non-medical
costs (including food and transport), income loss and
direct medical costs, including payments for labora-
tory tests, consultation fees and hospitalisation.
These costs are compounded by long health service
waiting times and the large numbers of clinic visits
before a diagnosis is made. Persons with presumptive
TB may also have comorbidities (such as HIV), which
can further complicate and delay diagnosis, especially
when sputum smear microscopy and chest radiogra-
phy are the only available diagnostic tools in that
catchment area. It is not surprising that financial
resources in poverty-stricken households can be
exhausted long before a definitive diagnosis of TB is
made.
As the Lancet Commission on building a TB-free
world emphasises, more attention needs to be paid to
implementing and integrating patient pathway anal-
yses into national TB programme activities so that
there is a far better understanding of how and where
persons with TB symptoms seek care and where
people fall out of the care cascade.4 Resources can
then be reallocated to where they are really needed to
identify the missing TB cases. Social protection
mechanisms for low-income countries, such as cash
transfers, transport reimbursement vouchers or social
health insurance schemes that are being tested in
middle-income, high TB burden countries in Asia,5
can be evaluated to determine whether they help in
reducing losses to follow-up at all stages of the care
cascade. The second pillar of the WHO End TB
Strategy emphasises bold policies and supportive
systems around social protection, poverty alleviation
and other determinants of TB, and these must lead to
bold actions to ensure that no one with TB is left
behind.
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